Despite having yet to save a mouse, last week a company created headlines when it said that it would cure all cancers -- in a year. Let's clarify what promise actually exists in the field, and what hurdles still need to be overcome.
Due to the opaque nature of the pharmaceutical industry’s disclosures, a study published in JAMA Internal Medicine sought to quantify a standard amount companies spent on the research and development of cancer drugs. Do these R&D costs justify such high prices and revenues?
The president's budget proposal for 2018 should raise some serious concerns. Cutting science funding, particularly that of the National Institutes of Health, is not aligned with his goal to "Make America Great Again."